Obsidian Therapeutics’ OBX-115 Receives the US FDA’s Fast Track Designation to Treat Advanced Melanoma
Shots:
- The US FDA has granted fast track designation to the company’s OBX-115 for metastatic or locally advanced melanoma patients who have relapsed and refractory after treatment with PD-1/PD-L1–based immune checkpoint inhibitors (ICI)
- OBX-115 is currently being assessed in a study for advanced or metastatic melanoma and non-small cell lung cancer (NSCLC), with recruitment completed in another FIH trial
- OBX-115 is an engineered TIL cell therapy featuring pharmacologically regulatable membrane-bound IL-15
Ref: Obsidian Therapeutics | Image: Obsidian Therapeutics
Related News:- Hinova Pharmaceuticals’ HP518 Gains the US FDA’s Fast Track Designation to Treat Triple-Negative Breast Cancer (TNBC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
